FDA approves world's first mRNA-based flu vaccine, signaling start of a new illness-prevention era

The US Food and Drug Administration's vaccine advisory committee has unanimously recommended the approval of Moderna's mFlusiva, a groundbreaking mRNA-based flu vaccine. This decision marks a significant step towards a new era in seasonal illness prevention, particularly for individuals aged 50 and older.

In advanced trials, mFlusiva proved to be about 27% more effective than traditional flu shots in preventing influenza. This improvement is substantial in a field where vaccine effectiveness can fluctuate significantly based on the match between vaccine strains and circulating viruses. The committee's recommendation covers two age groups: those aged 50 to 64 and those 65 and older. However, for the older demographic, where flu complications are more severe, Moderna will be required to conduct an additional post-market study.

Traditional flu vaccines, often produced using methods involving eggs or cell cultures, have a key limitation: manufacturers must select virus strains months in advance. This lead time can result in a weaker match if the virus mutates before winter. mRNA technology bypasses this by instructing the body's cells to produce a specific flu virus protein, prompting an immune response. This method also offers the advantage of potentially faster production times, allowing for quicker adaptation to evolving virus strains.